CR20230553A - Regímenes de dosificación expandidos para inhibidores de integrina - Google Patents
Regímenes de dosificación expandidos para inhibidores de integrinaInfo
- Publication number
- CR20230553A CR20230553A CR20230553A CR20230553A CR20230553A CR 20230553 A CR20230553 A CR 20230553A CR 20230553 A CR20230553 A CR 20230553A CR 20230553 A CR20230553 A CR 20230553A CR 20230553 A CR20230553 A CR 20230553A
- Authority
- CR
- Costa Rica
- Prior art keywords
- sup
- regímenes
- expandidos
- dosificación
- inhibidores
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 102000006495 integrins Human genes 0.000 title abstract 2
- 108010044426 integrins Proteins 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000004071 non-specific interstitial pneumonia Diseases 0.000 abstract 2
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163182757P | 2021-04-30 | 2021-04-30 | |
| PCT/US2022/072013 WO2022232838A1 (en) | 2021-04-30 | 2022-04-29 | Expanded dosage regimens for integrin inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20230553A true CR20230553A (es) | 2024-04-01 |
Family
ID=83848780
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20230553A CR20230553A (es) | 2021-04-30 | 2022-04-29 | Regímenes de dosificación expandidos para inhibidores de integrina |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230028658A1 (https=) |
| EP (1) | EP4329755A4 (https=) |
| JP (1) | JP2024517765A (https=) |
| KR (1) | KR20240024060A (https=) |
| CN (1) | CN117615760A (https=) |
| AU (1) | AU2022265730A1 (https=) |
| CA (1) | CA3173787A1 (https=) |
| CL (1) | CL2023003219A1 (https=) |
| CO (1) | CO2023016295A2 (https=) |
| CR (1) | CR20230553A (https=) |
| IL (1) | IL308063A (https=) |
| MX (1) | MX2023012794A (https=) |
| TW (1) | TW202308637A (https=) |
| WO (1) | WO2022232838A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10696672B2 (en) | 2016-12-23 | 2020-06-30 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
| TWI841573B (zh) | 2018-06-27 | 2024-05-11 | 美商普萊恩醫療公司 | 具有未分支連接子之胺基酸化合物及使用方法 |
| CN114173803A (zh) | 2019-04-08 | 2022-03-11 | 普利安特治疗公司 | 氨基酸化合物的剂型和方案 |
| EP4247472A4 (en) | 2020-11-19 | 2024-10-09 | Pliant Therapeutics, Inc. | INTEGRIN INHIBITORS AND USES THEREOF |
| US20250197393A1 (en) | 2023-12-14 | 2025-06-19 | Pliant Therapeutics, Inc. | Integrin inhibitor and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2984394T3 (es) * | 2016-11-08 | 2024-10-29 | Bristol Myers Squibb Co | Compuestos mono y espirocíclicos que contienen ciclobutano y azetidina como inhibidores de la integrina alfa v |
| WO2019118938A1 (en) * | 2017-12-15 | 2019-06-20 | Apellis Pharmaceuticals, Inc. | Dosing regimens and related compositions and methods |
| FI3761980T3 (fi) * | 2018-03-07 | 2024-02-21 | Pliant Therapeutics Inc | Aminohappoyhdisteitä ja käyttömenetelmiä |
| CN114173803A (zh) * | 2019-04-08 | 2022-03-11 | 普利安特治疗公司 | 氨基酸化合物的剂型和方案 |
| CN115989235A (zh) * | 2020-05-07 | 2023-04-18 | 普利安特治疗公司 | 使用氨基酸化合物治疗呼吸系统疾病的方法 |
| TW202329973A (zh) * | 2021-10-14 | 2023-08-01 | 美商普萊恩醫療公司 | 整合素抑制劑及其與其他藥劑併用之用途 |
-
2022
- 2022-04-29 MX MX2023012794A patent/MX2023012794A/es unknown
- 2022-04-29 IL IL308063A patent/IL308063A/en unknown
- 2022-04-29 WO PCT/US2022/072013 patent/WO2022232838A1/en not_active Ceased
- 2022-04-29 US US17/733,488 patent/US20230028658A1/en not_active Abandoned
- 2022-04-29 CR CR20230553A patent/CR20230553A/es unknown
- 2022-04-29 JP JP2023566804A patent/JP2024517765A/ja active Pending
- 2022-04-29 EP EP22796995.3A patent/EP4329755A4/en not_active Withdrawn
- 2022-04-29 CN CN202280046288.9A patent/CN117615760A/zh active Pending
- 2022-04-29 KR KR1020237041401A patent/KR20240024060A/ko not_active Withdrawn
- 2022-04-29 TW TW111116506A patent/TW202308637A/zh unknown
- 2022-04-29 AU AU2022265730A patent/AU2022265730A1/en not_active Abandoned
- 2022-04-29 CA CA3173787A patent/CA3173787A1/en active Pending
-
2023
- 2023-10-26 CL CL2023003219A patent/CL2023003219A1/es unknown
- 2023-11-29 CO CONC2023/0016295A patent/CO2023016295A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4329755A4 (en) | 2025-03-19 |
| CL2023003219A1 (es) | 2024-05-31 |
| IL308063A (en) | 2023-12-01 |
| MX2023012794A (es) | 2023-12-15 |
| TW202308637A (zh) | 2023-03-01 |
| CA3173787A1 (en) | 2022-11-03 |
| CN117615760A (zh) | 2024-02-27 |
| WO2022232838A1 (en) | 2022-11-03 |
| US20230028658A1 (en) | 2023-01-26 |
| JP2024517765A (ja) | 2024-04-23 |
| EP4329755A1 (en) | 2024-03-06 |
| KR20240024060A (ko) | 2024-02-23 |
| CO2023016295A2 (es) | 2023-12-11 |
| AU2022265730A1 (en) | 2023-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20230553A (es) | Regímenes de dosificación expandidos para inhibidores de integrina | |
| EP4509512A3 (en) | Amino acid compounds and methods of use | |
| CR20210041A (es) | Compuestos de aminoácidos con ligadores no ramificados y métodos de uso | |
| CR20210224A (es) | Compuestos de amoniácidos y métodos de uso | |
| ZA202209563B (en) | Biaryl derivatives as yap/taz-tead protein-protein interaction inhibitors | |
| MX2022013753A (es) | Tratamiento de enfermedades respiratorias con compuestos de aminoacidos. | |
| MX2024004438A (es) | Inhibidores de integrinas y usos de los mismos en combinacion con otros agentes. | |
| SA522431777B1 (ar) | مشتقات ألفا -d- جالاكتو بيرانوسيد | |
| PH12023552774A1 (en) | Nek7 inhibitors | |
| UA98757C2 (ru) | Бензамидные соединения, полезные как ингибиторы деацетилазы гистонов | |
| MX2022015495A (es) | Inhibidores de cinasa relacionada con el gen a nunca en mitosis (nek7). | |
| WO2024155965A3 (en) | Biomarkers for use in integrin inhibitor therapy | |
| ZA202407288B (en) | P2x3 inhibitor compound, salt thereof, polymorph thereof and use thereof | |
| JOP20240171A1 (ar) | مركبات يوراسيل بها استبدال بـ n3 على هيئة مثبطات trpa1 | |
| MX2023009954A (es) | Compuestos de aminopirimidina y métodos de uso de estos. | |
| JOP20200127A1 (ar) | مشتقات بيريدينون واستخدامها كمثبطات alk-2 انتقائية | |
| MX2025007577A (es) | Inhibidores de la integrina alfa-v-beta-8 y sus usos | |
| PL1858861T3 (pl) | Hamujące HIV 2-(4-cyjanofenylo)-6-hydroksyloaminopirymidyny | |
| GEAP202416376A (en) | Tetrahydrothieno pyridine derivatives as ddrs inhibitors | |
| MX2025006784A (es) | Inhibidores de fosfoglicerato deshidrogenasa para el tratamiento de la fibrosis | |
| MX2025006787A (es) | Inhibidores de fosfoglicerato deshidrogenasa para el tratamiento de fibrosis | |
| MX2024000620A (es) | Derivados de sulfamoilbenceno y sus usos. | |
| EA202092110A1 (ru) | Аминокислотные соединения и способы применения | |
| ZA202105115B (en) | Crystalline forms of a par4 inhibitor | |
| MX2009013865A (es) | Urea y derivados carbamato como inhibidores no nucleosidicos de la transcriptasa inversa. |